(Source: Arrowhead Research Corporation) PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a Phase 2a clinical study at The AASLD Liver Meeting 2015® demonstrating that ARC-520, its lead drug candidate against chronic hepatitis B infection (HBV), effectively reduced HBV viral antigens derived from cccDNA. HBV surface antigen (HBsAg) was reduced substantially with a maximum reduction of 1.9 logs (99%) and a mean maximum reduction of 1.5 logs (96.8%) in treatment naïve e-antigen (HBeAg)-positive patients. This direct antiviral effect was still evident 57 days after a single...
↧